Liver-related safety assessment of green tea extracts in humans: A systematic review of randomized controlled trials

European Journal of Clinical Nutrition

Volumn 70, Issue 11, 2016, Pages 1221-1229

  Isomura, T ^a,b,c,d   Suzuki, S ^c   Origasa, H ^d   Hosono, A ^c   Suzuki, M ^a   Sawada, T ^a   Terao, S ^a   Muto, Y ^a   Koga, T ^a  

^a Clinical Study Support   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; LIVER ENZYME; PLACEBO; ANTIOXIDANT; PLANT EXTRACT;

ABNORMAL LABORATORY RESULT; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TABLET FORMULATION; TEA; DRUG EFFECTS; FOOD SAFETY; LIVER;

ANTIOXIDANTS; FOOD SAFETY; HUMANS; LIVER; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TEA;

EID: 84969245568     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2016.78     Document Type: Review

References (65)

1. Katiyar S, Mukhtar H. Tea in chemoprevention of cancer. Int J Oncol 1996; 8: 221-238.
2. Henning SM, Fajardo-Lira C, Lee HW, Youssefian AA, Go VL, Heber D. Catechin content of 18 teas and a green tea extract supplement correlates with the antioxidant capacity. Nutr Cancer 2003; 45: 226-235.
3. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R. Safety of green tea extracts: A systematic review by the US Pharmacopeia. Drug Saf 2008; 31: 469-484.
4. Gloro R, Hourmand-Ollivier I, Mosquet B, Mosquet L, Rousselot P, Salamé E et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol 2005; 17: 1135-1137.
5. Galati G, Lin A, Sultan AM, O'Brien PJ. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med 2006; 40: 570-580.
6. Schmidt M, Schmitz HJ, Baumgart A, Guédon D, Netsch MI, Kreuter MH et al. Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem Toxicol 2005; 43: 307-314.
7. U. S Department of Health and Human Services. National Toxicology Program. Technical Report on the Toxicology Studies of Green Tea Extract in f344/ntac Rats and b6c3f1/n Mice and Toxicology and Carcinogenesis Studies of Green Tea Extract in Wistar han [crl:wi(han)] Rats and b6c3f1/n mice (gavage studies)
8. May 2014. Available from http://ntp. niehs. nih. gov/ntp/about-ntp/trpanel/ 2014/may/draft-tr585-508. pdf.
9. Yoshida M, Takahashi M, Inoue K, Nakae D, Nishikawa A. Lack of chronic toxicity and carcinogenicity of dietary administrated catechin mixture in Wistar Hannover GALAS rats. J Toxicol Sci 2011; 36: 297-311.
10. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C et al. Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009; 65: 331-341.
11. Navarro VJ, Bonkovsky HL, Hwang SI, Vega M, Barnhart H, Serrano J. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci 2013; 58: 2682-2690.
12. Hennekens CH, Buring JE, Mayrent SL. Epidemiology in Medicine. Little, Brown and Company: Boston, MA, USA, 1987.
13. International conference on harmonisation (ICH) harmonized tripartite guideline, E10 Choice of control group and related issues in clinical trials. Available from http://www. ich. org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E10/Step4/E10-Guideline. pdf.
14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-W94.
15. Loke YK, Price D, Herxheimer A. Adverse effects. In: Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5. 0. 1. The Cochrane Collaboration, 2008 Available from www. cochrane-handbook. org.
16. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J 2011; 343: d5928.
17. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23: 1351-1375.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
19. Higgins JPT, Green S. How to Cite this Version of the Handbook in Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0. The Cochrane Collaboration, 2011. Available from www. cochrane-handbook. org.
20. Princen HM, van Duyvenvoorde W, Buytenhek R, Blonk C, Tijburg LB, Langius JA et al. No effect of consumption of green and black tea on plasma lipid and antioxidant levels and on LDL oxidation in smokers. Arterioscler Thromb Vasc Biol 1998; 18: 833-841.
21. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9: 3312-3319.
22. Maron DJ, Lu GP, Cai NS, Wu ZG, Li YH, Chen H et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: A randomized controlled trial. Arch Intern Med 2003; 163: 1448-1453.
23. Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 2003; 31: 88-101.
24. Sonoda J, Koriyama C, Yamamoto S, Kozako T, Li HC, Lema C et al. HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking. Cancer Sci 2004; 95: 596-601.
25. Ullmann U, Haller J, Decourt JD, Girault J, Spitzer V, Weber P. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. Int J Vitam Nutr Res 2004; 74: 269-278.
26. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234-1240.
27. Chan CC, Koo MW, Ng EH, Tang OS, Yeung WS, Ho PC. Effects of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome-a randomized placebo-controlled trial. J Soc Gynecol Invest 2006; 13: 63-68.
28. Luo H, Tang L, Tang M, Billam M, Huang T, Yu J et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006; 27: 262-268.
29. Auvichayapat P, Prapochanung M, Tunkamnerdthai O, Sripanidkulchai BO, Auvichayapat N, Thinkhamrop B et al. Effectiveness of green tea on weight reduction in obese Thais: A randomized, controlled trial. Physiol Behav 2008; 93: 486-491.
30. Hill AM, Coates AM, Buckley JD, Ross R, Thielecke F, Howe PR. Can EGCG reduce abdominal fat in obese subjects J Am Coll Nutr 2007; 26: 396S-402S.
31. Rowe CA, Nantz MP, Bukowski JF, Percival SS. Specific formulation of Camellia sinensis prevents cold and flu symptoms and enhances gamma, delta T cell function: A randomized, double-blind, placebo-controlled study. J Am Coll Nutr 2007; 26: 445-452.
32. Widlansky ME, Hamburg NM, Anter E, Holbrook M, Kahn DF, Elliott JG et al. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 2007; 26: 95-102.
33. Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 2008; 27: 363-370.
34. Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H et al. Green tea extracts for the prevention of metachronous colorectal adenomas: A pilot study. Cancer Epidemiol Biomarkers Prev 2008; 17: 3020-3025.
35. Falsini B, Marangoni D, Salgarello T, Stifano G, Montrone L, Di Landro S et al. Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: A short-term study by pattern electroretinogram. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1223-1233.
36. Janjua R, Munoz C, Gorell E, Rehmus W, Egbert B, Kern D et al. A two-year, doubleblind, randomized placebo-controlled trial of oral green tea polyphenols on the long-term clinical and histologic appearance of photoaging skin. Dermatol Surg 2009; 35: 1057-1065.
37. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009; 2: 931-941.
38. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr 2010; 29: 31-40.
39. Shen CL, Chyu MC, Pence BC, Yeh JK, Zhang Y, Felton CK et al. Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report. BMC Complement Altern Med 2010; 10: 76.
40. Thielecke F, Rahn G, Bohnke J, Adams F, Birkenfeld AL, Jordan J et al. Epigallocatechin-3-gallate and postprandial fat oxidation in overweight/obese male volunteers: A pilot study. Eur J Clin Nutr 2010; 64: 704-713.
41. Brown AL, Lane J, Holyoak C, Nicol B, Mayes AE, Dadd T. Health effects of green tea catechins in overweight and obese men: A randomised controlled crossover trial. Br J Nutr 2011; 106: 1880-1889.
42. Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics A randomized, double-blind, and placebo-controlled clinical trial. Altern Med Rev 2011; 16: 157-163.
43. Hursel R, Westerterp-Plantenga MS. Consumption of milk-protein combined with green tea modulates diet-induced thermogenesis. Nutrients 2011; 3: 725-733.
44. Matsumoto K, Yamada H, Takuma N, Niino H, Sagesaka YM. Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: A randomized controlled trial. BMC Complement Altern Med 2011; 11: 15.
45. Ronzani G, Giaretta R, Morello M. Evaluation of oxidative stress and antioxidative action of green tea catechins in patients treated with tamoxifen: A randomized open-label, crossover study. Mediter J Nutr Metab 2011; 4: 127-132.
46. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C et al. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) 2012; 5: 1144-1154.
47. Dash C, Chung FL, Rohan JA, Greenspan E, Christopher PD, Makambi K et al. A six-month crossover chemoprevention clinical trial of tea in smokers and nonsmokers: methodological issues in a feasibility study. BMC Complement Altern Med 2012; 12: 96.
48. Loftis JM, Wilhelm CJ, Huckans M. Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: An 8-week, randomized, doubleblind, placebo-controlled study. Ther Adv Psychopharmacol 2013; 3: 21-27.
49. Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL et al. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 2012; 5: 290-298.
50. Yoshikawa T, Yamada H, Matsuda K, Niino H, Sagekawa YM, Kakuda T et al. Effects of short-term consumption of a large amount of tea catechins on chromosomal damage, oxidative stress markers, serum lipid, folic acid, and total homocysteine levels: A ramdomized, double-blind, controlled study. Jpn J Clin Pharmacol Ther 2012; 43: 9-16.
51. Dryden GW, Lam A, Beatty K, Qazzaz HH, McClain CJ. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1904-1912.
52. Roshdy E, Rajaratnam V, Maitra S, Sabry M, Allah AS, Al-Hendy A. Treatment of symptomatic uterine fibroids with green tea extract: A pilot randomized controlled clinical study. Int J Womens Health 2013; 5: 477-486.
53. Toolsee NA, Aruoma OI, Gunness TK, Kowlessur S, Dambala V, Murad F et al. Effectiveness of green tea in a randomized human cohort: relevance to diabetes and its complications. Biomed Res Int 2013; 2013: 412379.
54. Ioannidis JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009; 169: 1737-1739.
55. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009; 169: 1756-1761.
56. Ferner RE. Newly licensed drugs. Br Med J 1996; 313: 1157-1158.
57. Nagano J, Kono S, Preston DL, Mabuchi K. A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). Cancer Causes Control 2001; 12: 501-508.
58. Inoue M, Kurahashi N, Iwasaki M, Shimazu T, Tanaka Y, Mizokami M et al. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev 2009; 18: 1746-1753.
59. Ui A, Kuriyama S, Kakizaki M, Sone T, Nakaya N, Ohmori-Matsuda K et al. Green tea consumption and the risk of liver cancer in Japan: The Ohsaki Cohort study. Cancer Causes Control 2009; 20: 1939-1945.
60. Nechuta S, Shu XO, Li HL, Yang G, Ji BT, Xiang YB et al. Prospective cohort study of tea consumption and risk of digestive system cancers: results from the Shanghai Women's Health Study. Am J Clin Nutr 2012; 96: 1056-1063.
61. Boehm K, Borrelli F, Ernst E, Habacher G, Hung SK, Milazzo S et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2009; 3: CD005004.
62. Jin X, Zheng RH, Li YM. Green tea consumption and liver disease: A systematic review. Liver Int 2008; 28: 990-996.
63. Fon Sing M, Yang WS, Gao S, Gao J, Xiang YB. Epidemiological studies of the association between tea drinking and primary liver cancer: A meta-analysis. Eur J Cancer Prev 2011; 20: 157-165.
64. Stickel F, Kessebohm K, Weimann R, Seitz HK. Review of liver injury associated with dietary supplements. Liver Int 2011; 31: 595-605.
65. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic druginduced liver injury. Am J Gastroenterol 2014; 109: 950-966.